Pain relief for a rapid return to normal activities and better quality of life.
Sublimed relieves chronic pain associated with osteoarthritis of the knee using a discreet and flexible transcutaneous neurostimulation patch. It is available in France and several European countries.
The Sublimed device can be placed anywhere on the body, including joints.
Transcutaneous electrical neurostimulation has been used for 30 years to fight chronic pain. It inhibits pain signals and triggers the secretion of endorphins, the body’s natural analgesics. However, conventional equipment is cumbersome and impractical; 40% of patients give up using it for practicality reasons.
The startup Sublimed, born from the meeting between a CEA engineer and a pain center doctor, now offers a lightweight, miniaturized, and discreet device controlled via smartphone. A clinical study carried out on 110 patients confirmed its effectiveness for osteoarthritis of the knee, a result that led France’s national health insurance provider to approve the device for reimbursement. Thanks to a web platform, the patient can find their neurostimulation data and track quality of life indicators like sleep and resumption of walking and other daily activities.
Sublimed is based on a portfolio of six patents, including five CEA patents under license. It is collaborating with university medical centers to improve its technology and has been FDA-approved for the US market since 2021.
Key figure: 20,000
More than 20,000 patients in France have already used the actiTENS solution developed by Sublimed.
Prescribed for:
- Osteoarthritis of the knee
Technology:
- Slim, conformable pulse generator patch
- Miniaturized, wireless skin electrodes
- Remote electronic control
Year founded: 2015
Originating institute: CEA-Liten
www.subli-med.fr